Management of White Matter Hyperintensities

Primary Recommendation

The American Academy of Neurology recommends aggressively controlling systolic blood pressure as the single most important modifiable intervention for white matter hyperintensities, targeting SBP <120 mmHg in patients over 50 years old with blood pressure >130 mmHg 1, 2

Intensive vascular risk factor control is the cornerstone of WMH management, as WMHs represent a core feature of cerebral small vessel disease with direct implications for cognitive decline and dementia risk 3, 1
Target systolic blood pressure <120 mmHg in patients over 50 with SBP >130 mmHg and at least one additional vascular risk factor 1
Hypertension has the strongest evidence for association with WMH progression and cognitive impairment 1, 2
The SPRINT MIND trial demonstrated that intensive BP control (goal <120/<80) significantly reduced MCI risk after median 5.11 years, with absolute risk reduction of 0.4-0.7% per year 1
There is a linear relationship between lower blood pressure and lower cognitive impairment risk down to at least 100/70 mmHg 1
Diabetes at midlife is associated with 20-40% increased risk of vascular cognitive impairment 1

WMHs increase risk of cognitive impairment and dementia across all diagnostic categories, with strongest associations in MCI and post-stroke populations 3, 5
Prioritize executive function testing (Stroop test, Trails Making Test) as this domain shows the most consistent associations with WMHs, particularly frontal and parietal lesions 3, 5
Assess memory function, especially episodic memory, as temporal lobe WMHs show unique associations with medial temporal lobe structures 2
Perform global cognitive screening using MMSE at baseline for cross-study comparability 6, 5

Use FLAIR sequences as the primary modality for WMH detection 1, 2
Include diffusion-weighted imaging (DWI), T1-weighted, T2-weighted, and susceptibility scans (SWI or GRE) 1
Add 3D T1 volumetric sequences to assess medial temporal lobe atrophy, which correlates with temporal WMH 2
Repeat MRI at 12-24 month intervals, with 12-month intervals for patients showing cognitive decline 2, 4
Report WMHs using the Fazekas scale for visual rating 1, 6

Severe WMH at baseline produce the largest effect for incident dementia (HR 1.77, 95% CI 1.38-2.10) 2, 5
Periventricular WMHs have stronger associations with incident dementia (HR 1.51) compared to deep WMHs (HR 1.17) 5
MCI populations: WMHs are strongly associated with cognitive decline and conversion to dementia, representing the highest-risk group 3, 2, 5
Post-stroke populations: WMHs carry particularly strong prognostic significance for cognitive decline 2, 4
APOE ε4 status may modify the relationship between WMH and cognitive outcomes, particularly for memory and executive function domains 3, 2

Frontal WMH are most consistently associated with executive function decline 3, 5
Temporal lobe WMH show unique associations with medial temporal lobe structures and memory function 2
Corpus callosum (splenium) WMH are associated with both executive function and memory impairment 4
Corpus callosum (splenium) WMH correlate with medial-temporal atrophy 4